Abstract:
Background:
Atopic dermatitis (AD) is linked to increased cardiovascular risk. While GLP-1 receptor agonists (GLP-1RAs) show cardiometabolic benefits in the general population, their impact in patients with AD remains unclear.
Objective:
To evaluate whether GLP-1RA use is associated with a reduced risk of major adverse cardiovascular events (MACE) in patients with AD.
Methods:
This retrospective cohort study used TriNetX Research Network. Patients with AD ≥12 years old who used GLP-1RAs between April 2005 and December 2020 were 1:1 propensity-score matched to patients with AD not on GLP-1RA by demographic and cardiovascular risk factors. The primary outcome was incidence of MACE (cerebrovascular disease [CVD], heart failure [HF], atherosclerosis, ischemic heart disease [IHD], and percutaneous coronary intervention [PCI]) at 5, 10, and 20 years post-index date.
Results:
Of the 547,246 patients with AD, 24,936 (4.6%) used GLP-1RAs. After propensity-matching, at 20 years, patients with AD on GLP-1RA had lower odds of CVD (adjusted odds ratio [aOR] 0.718 [0.643–0.800]), HF (aOR 0.791 [0.732–0.854]), atherosclerosis (aOR 0.768 [0.715–0.826]), and IHD (aOR 0.900 [0.841, 0.963]), compared with patients with AD not using GLP-1RAs.
Conclusions:
In patients with AD, GLP-1RA use was associated with a reduced long-term risk of CVD, HF, IHD, and atherosclerosis, highlighting their potential cardiometabolic benefit in this population.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
0.03 MB0.00 MB 
